After selling Auris for $3.4 billion to J&J, CEO Frederic Moll and lead investor Ajay Royan come to Disrupt

Frederic Moll has to be one of the most successful inventors and entrepreneurs who is not yet a household name. Moll’s successes include the 22-year-old, publicly traded Expect to hear updates on investment in robotics, disruptions in the medical device world and much, much more at Disrupt SF in October when these two titans take the stage. Disrupt SF runs October 2 – October 4 at the Moscone Center in San Francisco. Tickets are available here. Original Article : HERE ; The Ultimate Survival Food: The Lost Ways

Neurobehavioral health company BlackThorn pulls in $76 million from GV to treat mental disorders

There are numerous challenges to finding effective treatments for mental disorders. However, BlackThorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put it ahead of the competition. Lucky for them, GV and other biotech investors have shown they agree by adding another $76 million in Series B financing to the coffers. Today, BlackThorn announced the close of its $76 million Series B round from GV, Scripps Research, Johnson & Johnson Innovation and a bevy of other biotech investment firms, including Polaris Partners, Premier Partners, Vertex Ventures HC, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners and Biomatics Capital. BlackThorn has …